Here are some of the major companies whose stocks moved on the week’s news.

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Lexington: Novo Nordisk A/S and Valo Health, Inc. have announced they have entered into an expanded agreement to discover and ...

Novo Nordisk A/S, a leading global healthcare company, and Valo Health, Inc. announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 ...

Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The company has a market cap of $384.27 billion, a P/E ratio of 27.71, a PEG ratio of 1.37 and a beta of 0.45.